Plus   Neg

Aldeyra Therapeutics Inc. (ALDX) Has Jumped To A 9-Month High On Study Results

Aldeyra Therapeutics Inc. (ALDX) reported results from its Phase 2a clinical trial of topical ocular ADX-102 in patients with dry eye disease Tuesday morning. The results showed statistically and clinically significant improvement across multiple sign and symptom endpoints.

Aldeyra Therapeutics gapped open sharply higher this morning and is now up 2.89 at $7.09 on the highest volume of the year. The stock has leaped to a 9 1/2 month high.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT